Trial Profile
Bioequivalence study of ARQ 197 amorphous and crystalline polymorphs A and B in normal healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Colorectal cancer; Gastric cancer; Germ cell cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors ArQule
- 21 Jun 2008 Status changed from recruiting to completed.
- 05 May 2008 New trial record.